Today: 23 June 2026
Browse Category

Pharmaceuticals 29 April 2026 - 13 May 2026

AbbVie is acquiring Apogee Therapeutics for $135.11 per share in cash, valuing Apogee at about $10.9 billion. The deal is expected to close in the third quarter and will bring AbbVie zumilokibart, an experimental long-acting drug for atopic dermatitis and other immune diseases. Apogee claims its top eczema drug could significantly reduce injection frequency compared to Dupixent, with Phase 3 trials planned for this year. Pfizer shares declined over the past week after CFO Dave Denton announced he will step down in August, with Cecile Guegan set to become interim CFO. Despite the leadership change, Pfizer maintained its 2026 forecast, but investors remain focused on succession, execution, and competition from obesity-drug makers. Pfizer’s stock has also been affected by concerns over pricing pressure, patent cliffs, and a longer path to profitability in obesity drugs. Meanwhile, Novo Nordisk shares rose about 5% as healthcare stocks gained favor among investors seeking defensive positions, even as the company reported strong demand for its Wegovy pill. Alumis shares surged 15.55% ahead of Phase 2b lupus results due in the third quarter and a planned psoriasis NDA filing in the fourth quarter. Outlook Therapeutics shares jumped 30% after the FDA accepted its resubmitted application for ONS-5010/LYTENAVA, with a key FDA decision expected on July 29. Other notable moves include AtaiBeckley’s 7.8% rise following the start of its BPL-003 Phase 3 program and CervoMed’s premarket jump after a director-linked trust purchased $3 million in units, following a recent $10.5 million private placement.
SELLAS Stock Jumps After AML Trial Moves Two Events From Final Readout

SELLAS Stock Jumps After AML Trial Moves Two Events From Final Readout

SELLAS Life Sciences said its pivotal REGAL leukemia trial has recorded 78 of 80 events needed for final analysis, triggering a rise in after-hours trading. The company reported a first-quarter net loss of $8.4 million but ended March with $107.1 million in cash. Research and development spending increased to $5.1 million. SELLAS expects its cash to fund operations for at least 12 months.
13 May 2026
···
Ernexa Stock’s 58% Jump Shows How Fast a Tiny Biotech Can Reprice on Ovarian-Cancer Hopes

Ernexa Stock’s 58% Jump Shows How Fast a Tiny Biotech Can Reprice on Ovarian-Cancer Hopes

Ernexa Therapeutics shares jumped 58.5% to $11.43 Tuesday after renewed investor focus on its preclinical ovarian-cancer therapy ERNA-101, following a May 11 investor event. Trading volume reached about 18.85 million shares. The company reported $8.3 million in cash as of April 30, less than needed for its 12-month plan, and may use an at-the-market stock sale to raise funds.
12 May 2026
··
Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Hims & Hers Health reports first-quarter results Monday after the market close, with Wall Street expecting about $617 million in revenue and EPS of 3 to 4 cents. Investors are watching whether its weight-loss business can grow after it stopped broadly marketing compounded GLP-1 drugs and shifted to FDA-approved options from Novo Nordisk. Hims shares closed at $28.46 Friday, rising to $29.07 after hours.
11 May 2026
····
Pfizer Stock Faces a Fresh COVID Patent Overhang as Investors Wait for Its Next Growth Act

Pfizer Stock Faces a Fresh COVID Patent Overhang as Investors Wait for Its Next Growth Act

A Delaware federal judge dismissed Acuitas Therapeutics’ attempt to clear Pfizer and BioNTech’s Comirnaty vaccine from GSK patent claims, citing lack of jurisdiction. The ruling does not address whether Comirnaty infringes GSK’s patents. Pfizer shares last closed at $25.68, down 1.42%. The company reaffirmed 2026 revenue guidance and reported first-quarter revenue of $14.5 billion.
11 May 2026
··
Hims & Hers Stock (HIMS) Faces a GLP-1 Test as Q1 Earnings Loom

Hims & Hers Stock (HIMS) Faces a GLP-1 Test as Q1 Earnings Loom

Hims & Hers Health shares rose 10.2% to $28.27 on Friday ahead of first-quarter results due Monday. Analysts expect Q1 revenue near $616.9 million and earnings of 3 cents per share. The company recently reached a deal with Novo Nordisk to offer Ozempic and Wegovy, and added Eli Lilly’s Zepbound and Foundayo to its platform. The FDA is considering tighter rules on compounding GLP-1 drugs.
9 May 2026
···
Novavax Stock Jumps As Pfizer Deal Cash Puts Vaccine Turnaround Back In Focus

Novavax Stock Jumps As Pfizer Deal Cash Puts Vaccine Turnaround Back In Focus

Novavax shares jumped 13% Friday after first-quarter revenue reached $139.5 million, beating estimates. Licensing and partner payments, including $30 million from Pfizer’s Matrix-M deal, offset weak COVID-19 vaccine demand. The stock traded at $10.45 with volume over 8.4 million shares. Investors await the company’s appearance at BofA’s health-care conference on May 13.
8 May 2026
···
Traws Pharma Stock Jumps As Biotech Targets Hantavirus After Cruise Ship Deaths

Traws Pharma Stock Jumps As Biotech Targets Hantavirus After Cruise Ship Deaths

Traws Pharma said it will advance clinical candidates for hantavirus after a cruise-ship outbreak killed three people, with no lead drug named yet. WHO confirmed five hantavirus cases on the MV Hondius, three fatal, and said person-to-person spread is limited. Traws shares jumped 21.8% after the announcement. The company has no approved products and recently raised $10 million in private funding.
8 May 2026
···
Novavax, Inc. Stock Jumps: Why Pfizer’s Matrix-M Deal Drove a Surprise Q1 Revenue Beat

Novavax, Inc. Stock Jumps: Why Pfizer’s Matrix-M Deal Drove a Surprise Q1 Revenue Beat

Novavax reported first-quarter revenue of $139.5 million, beating analyst expectations but down sharply from $666.7 million a year earlier. Licensing and partner payments, including $30 million from Pfizer, offset weak COVID-19 vaccine demand. Shares rose 1.7% Thursday after a 15.6% jump Wednesday, with trading volume spiking to 16.5 million shares. Product sales fell to $42.2 million, while licensing and other revenue reached $97.3 million.
7 May 2026
··
Bayer’s $2.45 Billion Perfuse Deal Puts Eye-Drug Pipeline Back in Focus

Bayer’s $2.45 Billion Perfuse Deal Puts Eye-Drug Pipeline Back in Focus

Bayer agreed to acquire Perfuse Therapeutics for up to $2.45 billion, including $300 million upfront, to gain access to a mid-stage eye-disease drug, PER-001. Eylea, Bayer’s top-selling eye drug, saw 2025 sales fall 5.9% to €3.11 billion amid generic competition. The deal awaits antitrust and shareholder approval. PER-001 is in Phase II trials for glaucoma and diabetic retinopathy.
6 May 2026
··
Novavax Stock Jumps as Pfizer Vaccine Deal Drives Big Q1 Revenue Beat

Novavax Stock Jumps as Pfizer Vaccine Deal Drives Big Q1 Revenue Beat

Novavax reported first-quarter revenue of $139.5 million, beating estimates as licensing and partner payments, including $30 million from Pfizer, offset weak COVID-19 vaccine sales. Shares rose 15.6% to $9.36 in afternoon trading. Product sales dropped to $42.2 million from $621.7 million a year ago. The company maintained its 2026 adjusted revenue forecast of $230 million to $270 million.
6 May 2026
··
Novo Nordisk Stock Jumps After Wegovy Pill Sales Surprise in Lilly Obesity Fight

Novo Nordisk Stock Jumps After Wegovy Pill Sales Surprise in Lilly Obesity Fight

Novo Nordisk raised its 2026 outlook after early U.S. sales of its new Wegovy weight-loss pill surpassed 2 million prescriptions since January, beating expectations. Shares jumped as much as 9.2% in Copenhagen. Adjusted first-quarter sales fell 10% to 70.06 billion crowns, but reported net sales rose 24% to 96.82 billion crowns after a U.S. drug pricing provision reversal.
6 May 2026
···
Pfizer Earnings Beat Wall Street, But The Patent Cliff Is Still The Story

Pfizer Earnings Beat Wall Street, But The Patent Cliff Is Still The Story

Pfizer posted first-quarter adjusted earnings of 75 cents per share on $14.45 billion in revenue, beating Wall Street forecasts. Sales of Eliquis and Padcev rose, offsetting steep declines in COVID products. The company maintained its 2026 revenue and profit outlook. Research and development expenses increased 12% as Pfizer invested in oncology and obesity drugs.
5 May 2026
···
Mirum Stock Jumps After Volixibat Trial Win Puts First PSC Itch Drug Within Reach

Mirum Stock Jumps After Volixibat Trial Win Puts First PSC Itch Drug Within Reach

Mirum Pharmaceuticals said its drug volixibat met the main goal in a 158-patient Phase 2b trial for primary sclerosing cholangitis, reducing itch scores more than placebo. Shares rose about 9% after the announcement. The company plans a pre-NDA meeting with the FDA this summer and aims to file for U.S. approval in the second half of 2026. No FDA-approved therapies currently exist for this rare liver disease.
4 May 2026
··
Recursion Pharmaceuticals Stock: Founder Chris Gibson to Leave Board as RXRX Nears Q1 Earnings

Recursion Pharmaceuticals Stock: Founder Chris Gibson to Leave Board as RXRX Nears Q1 Earnings

Recursion Pharmaceuticals said founder and board chair Chris Gibson will not seek re-election at the June 17 annual meeting, months after stepping down as CEO. The company reports first-quarter results May 6, with investors watching for updates on cash, clinical progress, and its AI drug platform. Recursion last reported $753.9 million in cash and narrowed its quarterly net loss. Gibson will remain chair until his term ends.
1 May 2026
··
Moderna Revenue Beat: Overseas Covid Shot Sales Jump, but $900 Million Charge Clouds the Turnaround

Moderna Revenue Beat: Overseas Covid Shot Sales Jump, but $900 Million Charge Clouds the Turnaround

Moderna’s first-quarter revenue jumped to $389 million, driven by international Covid vaccine sales, while U.S. revenue fell to $78 million. The company posted a net loss of $1.34 billion after a $900 million patent settlement charge. Shares fell 2.7% in early trading. Moderna kept its 2026 growth target and expects FDA action on its flu vaccine by August 5, 2026.
1 May 2026
·
Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

Eli Lilly raised its 2026 revenue forecast by $2 billion after first-quarter sales jumped 56% to $19.8 billion, driven by Mounjaro and Zepbound, which brought in $12.8 billion. Adjusted earnings reached $8.55 per share. The company cited strong demand but noted lower realized prices and competition from Novo Nordisk remain risks. Foundayo, Lilly’s new oral GLP-1 pill, launched in April but was not included in the quarter’s results.
30 April 2026
··
Teva Stock Jumps As Branded Drugs Start Carrying The Old Generics Giant

Teva Stock Jumps As Branded Drugs Start Carrying The Old Generics Giant

Teva reported first-quarter adjusted earnings of 53 cents per share on $3.98 billion revenue, beating estimates as sales of Austedo, Ajovy, and Uzedy climbed. Shares jumped 11% in New York trading. The company agreed to buy Emalex Biosciences for $700 million upfront, adding a late-stage Tourette syndrome drug candidate. Global generics revenue fell 16% amid increased competition.
29 April 2026
··
1 2 3 4 5 … 42

Stock Market Today

  • Qualcomm Shares Drop 2.05% Amid Earnings Concerns and Sector Lag
    June 22, 2026, 7:15 PM EDT. Qualcomm (QCOM) shares fell 2.05% to $221.49, underperforming the S&P 500's 0.37% decline in the latest session. The chipmaker's stock has dropped over 5% in the past month, lagging its sector's 4.52% gain and the S&P 500's 2.02% rise. Analysts expect Qualcomm's earnings per share (EPS) to fall 20.22% year-over-year to $2.21 and revenue to decline 6.46% to $9.7 billion for the quarter. The company holds a Forward P/E ratio of 21, below the industry's 53.67 average, and a high PEG ratio of 20.79, indicating expectations of slow earnings growth. Qualcomm has a Zacks Rank of #3 (Hold), reflecting cautious analyst sentiment amid a semiconductor industry ranked in the top 23% by Zacks Research.

Latest articles

Micron Shares Reach All-Time High with AI Memory Demand in Focus Ahead of Earnings

Micron Shares Reach All-Time High with AI Memory Demand in Focus Ahead of Earnings

23 June 2026
Micron Technology surged 6.9% to a record $1,211.38 after announcing a supply and investment deal with Anthropic, defying a tech market drop, as investors bet on AI-driven demand and raised analyst targets; Wednesday’s earnings will test if Micron can sustain gross margins above 80% and meet rising expectations amid tight competition and a global memory shortage.
Nexentis Soars 156% on AI Drug Discovery Plans, Shares Fall After the Bell

Nexentis Soars 156% on AI Drug Discovery Plans, Shares Fall After the Bell

23 June 2026
Nexentis Technologies shares soared 155.91% to $13.00 on massive volume after announcing an AI drug-discovery partnership and a $2.9 million stock-and-warrant financing at $7.056 per share, but fell 26.15% after hours as investors weighed the promise of new research against dilution risk and a going-concern warning.
Go toTop